This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Locating a subsidiary in close proximity to such an institution has advantages beyond pipeline talent, as there is the potential to access research and tap into networks for product development and clinical trials. Domestic market and transportation infrastructure. Industry clusters.
The status isn’t awarded lightly and Chiesi is the largest pharmaceuticalmanufacturer to be named a B Corp. “We Previously he was with Accenture where he led large teams in outsourcing projects across Europe and US for clients in the transportation and retail businesses.
With the myriad of guidance and recommendations to boost diversity and inclusion in oncology trials, , biotech and pharmaceuticalmanufacturers are left to interpret the criteria and implement them through tangible action. J National Comprehensive Cancer Network. 2019;17(11):1309-1316. doi:10.6004/jnccn.2019.7321
In this Q&A EPR speaks to Naser Al Yammahi the Deputy CEO of Hayat Biotech about pharmaceutical supply chain challenges and how they can be addressed. Yammahi was instrumental in building Hayat’s extensive distribution network needed to supply vaccines during the COVID-19 pandemic.
The pharmaceutical supply chain is a global and complex network that includes a wide range of stakeholders such as pharmaceuticalmanufacturers, wholesale distributors, and pharmacy benefit managers (PBM), to ensure efficient and timely delivery of medications to the patients.
In an age of disruption, technology is key to enabling pharmaceuticalmanufacturers monitor, track and control shipments and their processes. Pharmaceutical firms are changing the way they do business; the future winners will be highly automated and digitalised.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content